DDInter551 DDInter899
Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear to be associated with inhibition of prostaglandin synthesis via the arachidonic acid pathway. Diflunisal is used to relieve pain accompanied with inflammation and in the symptomatic treatment of rheumatoid arthritis and osteoarthritis.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Diflunisal {u} (Compound) resembles {v} (Compound) Salsalate
Diflunisal {u} (Compound) resembles {v} (Compound) Salicylic acid
Diflunisal {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olsalazine
Diflunisal {u} (Compound) binds {v} (Gene) PTGS2
Diflunisal {u} (Compound) upregulates {v} (Gene) HLA-DMA
Diflunisal {u} (Compound) palliates {v} (Disease) rheumatoid arthritis
Diflunisal {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Diflunisal {u} (Compound) downregulates {v} (Gene) EPN2
Diflunisal {u} (Compound) causes {v} (Side Effect) Photosensitivity reaction
Diflunisal {u} may cause a minor interaction that can limit clinical effects when taken with {v} Hyaluronidase
Diflunisal (Compound) resembles Salsalate (Compound)
Diflunisal (Compound) resembles Salicylic acid (Compound)
Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine
Diflunisal (Compound) binds PTGS2 (Gene)
Diflunisal (Compound) upregulates HLA-DMA (Gene)
Diflunisal (Compound) palliates rheumatoid arthritis (Disease)
Diflunisal (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class)
Diflunisal (Compound) downregulates EPN2 (Gene)
Diflunisal (Compound) causes Photosensitivity reaction (Side Effect)
Diflunisal may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase